Método Alternativo In Vitro para identificar sustancias con actividad endocrina

NICEATM coordinated an international interlaboratory validation study of the BG1Luc ER TA (LUMI-CELL®) test method developed by Xenobiotic Detection Systems, Inc. The study included three laboratories sponsored by NICEATM, the European Centre for the Validation of Alternative Methods, and the Japanese Center for the Validation of Alternative Methods. The goal of the validation study was to evaluate the usefulness of the BG1Luc ER TA test method as a screening test to identify substances with in vitro estrogen receptor (ER) agonist and antagonist activity.

The validation study of the BG1Luc ER TA test method has been completed and was the subject of a 2011 peer review by an ICCVAM-sponsored independent peer review panel. Following the recommendations of the independent peer review panel, ICCVAM recommends that the BG1Luc ER TA test method may be used as a screening test to identify substances with in vitro estrogen receptor agonist and/or antagonist activity. The ICCVAM recommendations to be transmitted to Federal agencies include recommendations on performance standards for the expedited validation of functionally and mechanistically similar test methods.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post

aetox

PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicinePD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine

Background: Anti-programmed cell dying protein 1 and programmed cell dying ligand 1 (PD-L1) brokers are broadly utilized in first-line and second-line therapy throughout completely different tumor sorts. Whereas immunohistochemistry-based assays are